The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Cidara Therapeutics Inc shares valued at $99,999,988 were purchased by RA CAPITAL MANAGEMENT, L.P. on Jun 26 ’25. At $44.00 per share, RA CAPITAL MANAGEMENT, L.P. acquired 2,272,727 shares. The insider’s holdings grew to 3,365,523 shares worth approximately $188.97 million following the completion of this transaction.
Also, Mineo Chrysa purchased 2,270 shares, netting a total of over 49,281 in proceeds. Following the buying of shares at $21.71 each, the insider now holds 2,270 shares.
Before that, Mineo Chrysa had added 1,050 shares to its account. In a trade valued at $24,614, the Director bought Cidara Therapeutics Inc shares for $23.44 each. Upon closing the transaction, the insider’s holdings increased to 1,050 shares, worth approximately $0.19 million.
Analysts at Citizens JMP started covering the stock with ‘”a Mkt outperform”‘ outlook in a report released in mid March. Earlier on December 13, 2024, RBC Capital Mkts initiated its rating. Their recommendation was “an Outperform” for CDTX stock.
Analyzing CDTX Stock Performance
On last trading session,, Cidara Therapeutics Inc [NASDAQ: CDTX] rose 7.44% to $56.15. The stock’s lowest price that day was $51.71, but it reached a high of $56.489 in the same session. During the last five days, there has been a surge of approximately 10.36%. Over the course of the year, Cidara Therapeutics Inc shares have jumped approximately 349.20%.
Support And Resistance Levels for Cidara Therapeutics Inc (CDTX)
RSI (Relative Strength Index) is 75.00 on the 14-day chart, showing overbought technical sentiment.
Is Cidara Therapeutics Inc subject to short interest?
Stocks of Cidara Therapeutics Inc saw a sharp rise in short interest on 2025-06-13 jumping by 0.2 million shares to 0.65 million. Data from Yahoo Finance shows that the short interest on 2025-05-15 was 0.45 million shares. A jump of 31.31% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 3.1 of the overall float, the days-to-cover ratio (short ratio) jumped to 3.1.
Which companies own the most shares of Cidara Therapeutics Inc (CDTX)?
In terms of Cidara Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 57.5 in the next 12 months, up nearly 10.03% from the previous closing price of $52.26. Analysts anticipate Cidara Therapeutics Inc stock to reach 69 by 2025, with the lowest price target being 46. In spite of this, 1 analysts ranked Cidara Therapeutics Inc stock as Buy at the end of 2025. On November 08, 2024, Guggenheim assigned a price target of “a Buy” to the stock and initiated coverage with a $33.
